Former CMS Administrator: "'Blunt Instrument' Policies an Increasingly Bad Fit in Era of Personalized Health Care"

"We don't seem to be making much progress politically; it's easy to be cynical when it comes to health care," said McClellan, current Director of the Engelberg Center for Health Care Reform and Senior Fellow at the Brookings Institute. "Just focusing on cost reduction doesn't do much to solve the problem of getting more value for what we are spending."

McClellan characterized as unsustainable short-term strategies such as across-the-board reductions in Medicare reimbursement fees for physicians and coverage policies that prevent access to the latest biomedical technologies; yet indicated a shift is clearly afoot within both political parties as candidates move towards a value-based, quality-focused approach to improving care for millions of Americans.

"There simply isn't any additional funding available for new health care programs, but this presents the foundation for changing health care," said McClellan. "Each of the political candidates is demonstrating a new emphasis on improving quality and efficiency of care."

McClellan highlighted improved management of chronic diseases and complications; improved identification of patients at risk for chronic diseases; an increased focus on wellness; and better support for navigation of the health care system as strategies espoused by both parties that have the potential to improve quality of care.

"Both party's candidates are placing a greater emphasis than ever before on strategies like chronic disease prevention and healthcare information technology," said McClellan.

McClellan commented on additional issues facing the current and future health care landscape:

    -- Recent rapid advancements in gene-based care such as proteomics and
       genomics, RNA interference, regenerative medicine and epigenetics are
       ushering in the "Biomedical Century" and introducing a sea change in
       personalized medicine that makes "all the spending worth it."

    -- A key driver of cost is not rising prices or an aging population; in
       fact, the key driver is simply more people getting more treatments
       combined with longer life expectancy.  However, there is a major
       problem with the underuse of services for chronic disease management,
       as patients with chronic diseases get appropriate treatment only about
       55 percent of the time.

    -- While the introduction of biosimilars holds tremendous promise for
       financial relief, it is unlikely that Congress will act on legislation
       this year to advance the policies around the emerging therapeutic
       category.  McClellan also noted that the Food and Drug Administration
       makes a clear distinction between generic similars and interchangeables
       in oral medications, a distinction that will prove to be inapplicable
       to biologics and could present unique challenges in crafting
       appropriate legislation.

About Medco

Medco Health Solutions, Inc., (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2007 total net revenues of more than $44 billion. Medco's prescription drug benefit programs, covering approximately one-in-five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program and those served by its specialty pharmacy segment, Accredo Health Group. Medco, the world's most advanced pharmacy(TM), is positioned to serve the unique needs of patients with chronic and complex conditions through its Medco Therapeutic Resource Centers(R), including its enhanced diabetes pharmacy care practice through the Liberty acquisition. Medco is the highest-ranked independent pharmacy benefit manager on the 2008 Fortune 100 list. On the Net: http://www.medco.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

SOURCE Medco Health Solutions, Inc.

Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze, Daily News

Tags: Pharmaceuticals, Biotechnology, Healthcare, Health, , florida

   _   _

         

Is your favorite bookmark site missing? Ask for it.